Opinion
Video
Author(s):
The panel examines the characteristics of patients with non-small cell lung cancer (NSCLC) without actionable alterations who might be the best candidates for frontline treatment with either sacituzumab govitecan or datopotamab deruxtecan (Dato-DXd) and identifies the persisting unmet needs for this patient population.
De-Escalation Strategies, Biomarkers Could Refine Treatment Algorithm for Early-Stage HER2+ Breast Cancer
Dr Feldman on New Approaches for Decreasing the Risk of Breast Cancer–Related Lymphedema
Dr Mukhtar on Challenges in the Diagnosis and Management of Invasive Lobular Carcinoma
Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer
2 Commerce Drive
Cranbury, NJ 08512